Ziabetus (Prediabetes): A Harbinger of Critical Stage in the Continuum of Glucose Metabolism Disorder: A Review


Background: Prediabetes is a metabolic condition characterized by blood glucose levels higher than normal but below the threshold for diabetes mellitus. It represents a critical stage in the progression towards type 2 diabetes mellitus (T2DM) and is associated with an increased risk of cardiovascular disease and other complications. The two major pathophysiologic defects responsible for losing glucose tolerance are insulin resistance and β-cell glucose insensitivity, both appearing in subjects of Intermediate Hyperglycaemia. In classical literature, Unani physicians have described the initial symptoms and factors leading to the pathology, the risk factors are described in terms of ‘Su-e-mizaj’ as per the concept of Tibb. So, it is considered in the context of Ziabetus which is described as a disease that develops due to Sue-mizaj haar (abnormal hot temperament). The symptoms mentioned in Unani medicine are increased frequency of micturition (ants and flies are attracted to urine), increased thirst, nocturia, dryness of mouth and whole body, fatigue, loss of weight, malaise, and cramps in lower extremities. The modern drug-based approach for the management of Intermediate Hyperglycaemia is associated with inherent drawbacks, including toxicity, tolerability, cost, and efficacy. Objective: The purpose of this review is to provide an in-depth understanding of prediabetes concerning the classical literature of Greek medicine based on the analysis of certain parameters like etiopathophysiology, current diagnostic criteria, risk factors, and evidence-based management strategies. By synthesizing findings from epidemiological studies, and clinical trials, this paper aims to enhance understanding of prediabetes and facilitate effective preventive measures and interventions.

Keywords: Prediabetes, Intermediate hyperglycaemia, Impaired Glucose Tolerance, Impaired Fasting Glucose, Insulin Resistance.

Keywords: Prediabetes, Intermediate hyperglycaemia, Impaired Glucose Tolerance, Impaired Fasting Glucose, Insulin Resistance


Download data is not yet available.

Author Biographies

Rafat Afzal, P.G Scholar, Dept. of Ilaj Bit Tadbeer, AKTC, AMU, Aligarh, India

P.G Scholar, Dept. of Ilaj Bit Tadbeer, AKTC, AMU, Aligarh, India

Asia Sultana, Professor & HOD, Dept. of Ilaj Bit Tadbeer, AKTC, AMU, Aligarh, India

Professor & HOD, Dept. of Ilaj Bit Tadbeer, AKTC, AMU, Aligarh, India

Mohammad Shoaib, Assistant Professor, Dept. of Ilaj Bit Tadbeer, AKTC, AMU, Aligarh, India

Assistant Professor, Dept. of Ilaj Bit Tadbeer, AKTC, AMU, Aligarh, India

Hamid Ashraf, Associate Professor, Rajiv Gandhi centre for Diabetes & Endocrinology, JNMC, AMU, Aligarh, India

Associate Professor, Rajiv Gandhi centre for Diabetes & Endocrinology, JNMC, AMU, Aligarh, India


1. ADA (Am. Diabetes Assoc.). Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes. Diabetes Care 43:Suppl. 2020;1S14-31 https://doi.org/10.2337/dc20-S002 PMid:31862745
2. ADA (Am. Diabetes Assoc.). Standards of medical care in diabetes. Diabetes Care 2010;33:Suppl:1S11-61 https://doi.org/10.2337/dc10-S011 PMid:20042772 PMCid:PMC2797382
3. Fajans SS. I. Identification of chemical diabetes. The definition of chemical diabetes. Metabolism.1973;22:2211-17 https://doi.org/10.1016/0026-0495(73)90163-7 PMid:4631671
4. Herron CA.. Screening in diabetes mellitus: report of the Atlanta workshop. Diabetes Care.1979;2:4357-62 https://doi.org/10.2337/diacare.2.4.357 PMid:41691
5. Qarshi MH, Jameul Hikmat. Vol. II. New Delhi: Idara Kitabul Shifa, 2011.864-70.
6. Khan MA. Romooze Aazm (Farsi). Vol. I. New Delhi: CCRUM, 2006.139-41.
7. Nazamuddin M. Evaluation of hypoglycemic activity of Qurs Tabasheer in experimentally induced diabetes in animal model [dissertation]. Dept. of Ilmul Advia (Pharmacology), 2013. NIUM, Rajiv Gandhi University of Health Sciences (RGUHS), Bangalore, Karnataka, India.
8. WHO (World Health Organ.) Definition and diagnosis of diabetes mellitus and intermediate Rep., 2006. WHO Geneva:
9. Nathan DM, Balkau B, Bonora E, Borch-Johnsen K, Buse JB et al. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009. 32:71327-34 https://doi.org/10.2337/dc09-1777
10. Natl. Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes.1979;28:121039-57 https://doi.org/10.2337/diab.28.12.1039 PMid:510803
11. Genuth S, Alberti KGMM, Bennett P, Buse J, Defronzo R et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:113160-67 https://doi.org/10.2337/diacare.26.11.3160 PMid:14578255
12. Glauber H., Vollmer W.M., Nichols G.A. A Simple Model for Predicting Two-Year Risk of Diabetes Development in Individuals with Prediabetes. Perm. J. 2018; 22 https://doi.org/10.7812/TPP/17-050 PMid:29309270 PMCid:PMC5760055
13. American Diabetes Association Professional Practice Committee. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes. 2022; 45:S17-S38. https://doi.org/10.2337/dc22-S002 PMid:34964875
14. Khan M Ajmal. Haziq. New Delhi: Jasem Book Depot, 1983. 387-90.
15. Majoosi AA. Kamilus Sana'ah, (Urdu translation by Kantoori GH). 1st ed. New Delhi: Idara Kitabus Shifa, 2010. 154,467,472,527.
16. Jurjani AHI. Zakhira Khawarzam Shahi (Urdu translation by Khan HH) Vol. II, Part 6. New Delhi: Idara Kitabul Shifa, 1996. 540-41.
17. Ibne Zohar. Kitabut Taiseer (Urdu translation by CCRUM). New Delhi: CCRUM, 1986. 160-63.
18. Ibne Hubal B. Kitabul Mukhtarat Fil Tib (Urdu translation by CCRUM). Vol. III. New Delhi: CCRUM, 2005. 326-8.
19. Tabák, A. G., et al. Prediabetes: A high-risk state for diabetes development. The Lancet, 2012;379(9833):2279-2290. https://doi.org/10.1016/S0140-6736(12)60283-9 PMid:22683128
20. Huang, Y., et al. Global prevalence of prediabetes among adults: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2016;123:48-55.
21. Diabetes Prevention Program Research Group, The Prevalence of Retinopathy in Impaired Glucose Tolerance and Recent-Onset Diabetes in the Diabetes Prevention Program. Diabetes Med. 2007;24:137-144. https://doi.org/10.1111/j.1464-5491.2007.02043.x PMid:17257275 PMCid:PMC2267935
22. Lee C.C., Perkins B.A., Kayaniyil S., Harris S.B., Retnakaran R., Gerstein H.C., Zinman B., Hanley A.J. Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. Diabetes Care. 2015; 38:793-800. https://doi.org/10.2337/dc14-2585 PMid:25665810
23. Echouffo-Tcheugui J.B., Narayan K.M., Weisman D., Golden S.H., Jaar B.G. Association between Prediabetes and Risk of Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Diabetes Med. 2016; 33:1615-1624. https://doi.org/10.1111/dme.13113 PMid:26997583
24. Huang Y., Cai X., Mai W., Li M., Hu Y. Association between Prediabetes and Risk of Cardiovascular Disease and All Cause Mortality: Systematic Review and Meta-Analysis. BMJ. 2016; 355:i5953. https://doi.org/10.1136/bmj.i5953 PMid:27881363 PMCid:PMC5121106
25. Ramya S, Murugan M, Krishnaveni K, Sabitha M, Kandeepan C, Jayakumararaj R. In-silico ADMET profile of Ellagic Acid from Syzygium cumini: A Natural Biaryl Polyphenol with Therapeutic Potential to Overcome Diabetic Associated Vascular Complications. Journal of Drug Delivery and Therapeutics. 2022;12(1):91-01. https://doi.org/10.22270/jddt.v12i1.5179
26. Prentki, M., & Nolan, C. J. Islet β cell failure in type 2 diabetes. Journal of Clinical Investigation, 20061;16(7):1802-1812. https://doi.org/10.1172/JCI29103 PMid:16823478 PMCid:PMC1483155
27. The HAPO Study Cooperative Research Group Hyperglycemia and Adverse Pregnancy Outcomes. N. Engl. J. Med. 2008; 358:1991-2002. https://doi.org/10.1056/NEJMoa0707943 PMid:18463375
28. Billings, L. K., & Florez, J. C. The genetics of type 2 diabetes: What have we learned from GWAS? Annals of the New York Academy of Sciences, 2010;1212(1):59-77. https://doi.org/10.1111/j.1749-6632.2010.05838.x PMid:21091714 PMCid:PMC3057517
29. Lyssenko, V., & Laakso, M. Genetic screening for the risk of type 2 diabetes: Worthless or valuable? Diabetes Care, 2013.;36(Suppl 2):S120-S126. https://doi.org/10.2337/dcS13-2009 PMid:23882036 PMCid:PMC3920800
30. Abdul-Ghani, M. A., & DeFronzo, R. A. Pathogenesis of insulin resistance in skeletal muscle. Journal of Biomedicine and Biotechnology, 2010, 476279. https://doi.org/10.1155/2010/476279 PMid:20445742 PMCid:PMC2860140
31. Samuel, V.T., & Shulman, G.I. The pathogenesis of insulin resistance:Integrating signaling pathways and substrate flux. Journal of Clinical Investigation, 2016;126(1):12-22. https://doi.org/10.1172/JCI77812 PMid:26727229 PMCid:PMC4701542
32. Kahn, S. E., & Hull, R. L. Pathophysiology of type 2 diabetes mellitus. Endocrinology and Metabolism Clinics of North America, 2006. 35(3), 581-610. https://doi.org/10.1016/S0889-8529(07)70003-8 PMid:17424673
33. Mali RP, Rao PS, Jadhav RS. A Review on Pharmacological Activities of Calotropis Procera. Journal of Drug Delivery and Therapeutics. 2019;9(3-s):947-51.
34. Hu, F. B. Globalization of diabetes: The role of diet, lifestyle, and genes. Diabetes Care, 2011;34(6):1249-1257. https://doi.org/10.2337/dc11-0442 PMid:21617109 PMCid:PMC3114340
35. Danaei, G., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. The Lancet, 2011. 378(9785), 31-40. https://doi.org/10.1016/S0140-6736(11)60679-X PMid:21705069
36. Anzar MA, Shamim A, Nafis H, Tanwir MA. Drugs Indicated for The Management of Ziabetus Shakri (Diabetes Mellitus) in Unani Medicine-An Overview. International Journal of Pharmamedix India 2013;1(3):460-74.
37. Ibn Sina, Al Qanoon Fil Tib. (Urdu translation by Kantoori GH). Vol. II. New Delhi: Idara Kitabul Shifa, 2007.1031-33,353-54.
38. Ibne Sina. Al Qanoon Fit Tib (Arabic). 1st ed. Vol. III, Part 2. New Delhi: Jamia Hamdard, 1408Hijr 263-64, 783-85.
39. Samarqandi N. Sharah Asbab (Urdu translation by Ayyub M.). Vol. III. New Delhi: Aijaz Pulishing House, 38-48, YNM
40. Khan AM, Rzaq MA, Ahad MA. Mojizul Mahsha (Arabi). New Delhi: Mujtabai, 1415 Hijri. 387-78.
41. American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes. Diabetes Care, 2021;44(Supplement 1):lS15-S33. https://doi.org/10.2337/dc21-S002 PMid:33298413
42. Centers for Disease Control and Prevention. Prediabetes - Your Chance to Prevent Type 2 Diabetes, 2021. Retrieved from https://www.cdc.gov/diabetes/basics/prediabetes.html, accessed 4/2024.
43. Ziegler, D., Rathmann, W., & Meisinger, C. Polyneuropathy in Diabetes Prediabetes: Symptom Pattern and Prevalence. Diabetes Care, 2009;32(1):163-165.
44. Liew, G., Michaelides, M., & Bunce, C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years),1999-2000 with 2009-2010. BMJ Open, 2016. 6(2), e010201.
45. Schoen, E., & Narayan, K. M. Incidence of Chronic Complications in Prediabetic Cohorts. Diabetes Care, 2010. 33(3), 514-520.
46. Callaghan, B. C., & Feldman, E. L. The metabolic syndrome and neuropathy: therapeutic challenges and opportunities. Annals of Neurology, 2012;72(6):807-816.
47. Bytzer, P., Talley, N. J., & Leemon, M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Archives of Internal Medicine, 2001. 161(16):1989-1996. https://doi.org/10.1001/archinte.161.16.1989 PMid:11525701
48. Eldin W, Shehab E M, Shokar A. Prediabetes:a must to recognize disease state. International Journal of Clinical Practice. 2018; 4:642-648. https://doi.org/10.1111/j.1742-1241.2008.01705.x PMid:18266711
49. Nasir A, Fatma G, Concept and Therapeutic Approach of Intermediate Hyperglycemia with Special Reference to Unani Medicine
50. Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A. & Nathan, D. M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 2002;346(6), 393-403 https://doi.org/10.1056/NEJMoa012512 PMid:11832527 PMCid:PMC1370926
51. Firdaus S, Anwar AI, Khan AA, Ahmed S, Classical Review Of Ziabetus (Diabetes) In Unani Treatise With Insightful Perspectives Of Preventive Measures.
52. Sina. I Alqanoon fil Tibb (Urdu translation by Ghulam Husnain Kantoori). published by Idara Kitab-ul- Shifa, Darya Ganj, New Delhi. 1933; 3:1031-1033, 353- 354.
53. Khan Mohammad Azam. Akseer-e-Azam. published by IdaraKitab-ul- Shifa, Darya Ganj, New Delhi. 2011;705-709
54. Razi Abu Bakr Muhammad bin Zakariya. Kitabul Havi (Urdu translation by CCRUM). 2002;10:181-206.
55. Kar A, Choudhary BK, Bandyopadhyay NG. Comparative evaluation of hypoglycaemic activity of some Indian medicinal plants in alloxan diabetic rats. J Ethnopharmacol, 2003; 84(1):105-108 https://doi.org/10.1016/S0378-8741(02)00144-7 PMid:12499084
56. Dey L, Attele AS, Yuan CS. Alternative therapies for type 2 diabetes. Altern Med Rev., 2002; 7(1):45-58
58 Views | 55 Downloads
How to Cite
Afzal R, Sultana A, Shoaib M, Ashraf H. Ziabetus (Prediabetes): A Harbinger of Critical Stage in the Continuum of Glucose Metabolism Disorder: A Review. JDDT [Internet]. 15May2024 [cited 24Jun.2024];14(5):229-33. Available from: https://jddtonline.info/index.php/jddt/article/view/6543